Sodium Oxybate in Alcohol-Responsive Essential Tremor of Voice: An Open-Label Phase II Study

被引:3
|
作者
O'Flynn, Lena C. [1 ,2 ,3 ]
Frucht, Steven J. [4 ]
Simonyan, Kristina [1 ,2 ,3 ,5 ,6 ,7 ]
机构
[1] Massachusetts Eye & Ear, Dept Otolaryngol Head & Neck Surg, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Harvard Univ, Program Speech Hearing Biosci & Technol, Boston, MA USA
[4] NYU Langone Hlth, Dept Neurol, New York, NY USA
[5] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
[6] Massachusetts Eye & Ear, Dept Otolaryngol Head & Neck Surg, 243 Charles St,Suite 421, Boston, MA 02114 USA
[7] Harvard Med Sch, 243 Charles St,Suite 421, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
voice tremor; sodium oxybate; treatment; alcohol; MOVEMENT-DISORDERS; SENSITIVITY; RECEPTORS; TARGETS; TRIAL;
D O I
10.1002/mds.29529
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundEssential tremor of voice (ETv) is characterized by involuntary oscillations of laryngeal and upper airway muscles, causing rhythmic alterations in pitch and loudness during both passive breathing and active laryngeal tasks, such as speaking and singing. Treatment of ETv is challenging and typically less effective compared with treatment of ET affecting extremities. ObjectiveWe conducted a proof-of-concept, open-label phase II study to examine the efficacy and central effects of sodium oxybate in patients with alcohol-responsive ETv. MethodsAll subjects received 1.0 to 1.5 g of oral sodium oxybate and underwent brain functional magnetic resonance imaging. The primary endpoint was the number of patients (% from total) with reduced ETv symptoms by at least 10% at about 40 to 45 minutes after sodium oxybate intake based on the combined visual analog scale score of ETv symptom severity. The secondary endpoint included changes in brain activity after sodium oxybate intake compared to baseline. ResultsSodium oxybate reduced ETv symptoms on average by 40.8% in 92.9% of patients. Drug effects were observed about 40 to 45 minutes after intake, lasting about 3.5 hours, and gradually wearing off by the end of the fifth hour. The central effects of sodium oxybate were associated with normalized activity in the cerebellum, inferior/superior parietal lobules, inferior frontal gyrus, and insula and re-established functional relationships between these regions. ConclusionsSodium oxybate showed high efficacy in ETv patients, with a likely central action on disorder pathophysiology. Sodium oxybate may be an effective novel oral drug for treatment of alcohol-responsive ETv patients. & COPY; 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
引用
收藏
页码:1936 / 1944
页数:9
相关论文
共 50 条
  • [21] Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
    Spaeth, Michael
    Alegre, Cayetano
    Perrot, Serge
    Wang, Youyu Grace
    Guinta, Diane R.
    Alvarez-Horine, Sarah
    Russell, Irwin Jon
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (06)
  • [22] Open-label pilot study of memantine for alcohol dependence
    Arias, Albert
    Covault, J.
    AMERICAN JOURNAL ON ADDICTIONS, 2006, 15 (04): : 316 - 317
  • [23] Baclofen for alcohol dependence: A preliminary open-label study
    Flannery, BA
    Garbutt, JC
    Cody, MW
    Renn, W
    Grace, K
    Osborne, M
    Crosby, K
    Morreale, M
    Trivette, A
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2004, 28 (10) : 1517 - 1523
  • [24] Memantine for Alcohol Dependence: An Open-label Pilot Study
    Arias, Albert J.
    Feinn, Richard
    Covault, Jonathan
    Kranzler, Henry R.
    ADDICTIVE DISORDERS & THEIR TREATMENT, 2007, 6 (02): : 77 - 83
  • [25] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [26] Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
    Aida Muhic
    Hans Skovgaard Poulsen
    Morten Sorensen
    Kirsten Grunnet
    Ulrik Lassen
    Journal of Neuro-Oncology, 2013, 111 : 205 - 212
  • [27] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [28] Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
    Muhic, Aida
    Poulsen, Hans Skovgaard
    Sorensen, Morten
    Grunnet, Kirsten
    Lassen, Ulrik
    JOURNAL OF NEURO-ONCOLOGY, 2013, 111 (02) : 205 - 212
  • [29] Late Breaking Abstract - Nintedanib for Lymphangioleiomyomatosis: an open-label phase II study
    Harari, Sergio
    Elia, Davide
    Caminati, Antonella
    Geginat, Jens
    Luisi, Francesca
    Pelosi, Giuseppe
    Specchia, Claudia
    Torre, Olga
    Vasco, Chiara
    Zompatori, Maurizio
    Cassandro, Roberto
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [30] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767